Hangzhou Yusheng

Hangzhou Yusheng Pharmaceutical is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages a structure-based drug design (SBDD) platform to target challenging protein-protein interactions (PPIs) in oncology and metabolic diseases. Its lead program, YS-101, is a potent and selective MDM2-p53 inhibitor currently undergoing clinical evaluation for the treatment of various solid tumors and hematological malignancies. Hangzhou Yusheng aims to address significant unmet medical needs by developing first-in-class or best-in-class medicines through its internal R&D capabilities. The company is backed by prominent venture capital firms including Qiming Venture Partners and TF Capital.